JPRN-UMIN000027887
Completed
Phase 2
Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer - TRIUMPH study
ational Cancer Center Hospital East0 sites30 target enrollmentJuly 26, 2017
Conditionscolorectal cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- colorectal cancer
- Sponsor
- ational Cancer Center Hospital East
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Has a known history of bone marrow transplantation or organ transplantation 2\)Has a positive result on the serum pregnancy test 3\)Is judged by the investigator to be inappropriate for study participation for any reason.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study to assess the efficacy and the safetyof front-line therapy (Fludarabine, Cyclophosphamide and Ofatumumab) in young (=65 yrs) patientswith Chronic Lymphocytic Leukemia (CLL)EUCTR2011-005329-27-ITG.I.M.EM.A.Gruppo Italiano Malattie Ematologiche dell'Adulto
Recruiting
Phase 2
A multicenter phase II study to evaluate the efficacy and safety of fixed-duration sequential treatment combined with novel agents and autologous stem cell transplantation for newly diagnosed elderly multiple myeloma. -JSCT EMM21JPRN-jRCTs071210084Kikushige Yoshikane75
Recruiting
Phase 1
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.BRAF V600E mutated and microsatellite stable (MSS) advanced colorectal cancer (aCRC) initially resectable or potentially resectableMedDRA version: 21.0Level: PTClassification code: 10052360Term: Colorectal adenocarcinoma Class: 100000004864Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-502413-29-00Asociacion Grupo Tratamiento De Tumores Digestivos70
Active, not recruiting
Phase 1
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10029261Term: Neuroblastoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-005617-14-DKovartis Pharma AG230
Active, not recruiting
Phase 1
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)EUCTR2021-005617-14-CZovartis Pharma AG230